Jeil Pharm Total Assets
Jeil Pharm total assets. Based on the latest financial reports, Jeil Pharm (002620) holds total assets worth ₩891.76 Billion KRW (≈ $604.34 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Jeil Pharm worth for the company's overall valuation and market capitalisation.
Total Assets of Jeil Pharm (2011–2025)
Total assets of Jeil Pharm from 2011 to 2025. This chart illustrates how Jeil Pharm's total assets have evolved over time, based on quarterly financial data. See Jeil Pharm share price for real-time trading data and today's change.
Jeil Pharm - Asset Composition Analysis
Jeil Pharm Total Assets Breakdown (December 2025)
Jeil Pharm total assets breakdown as of December 2025. Jeil Pharm's total assets of ₩891.76 Billion consist of 42.6% current assets and 57.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 6.4% |
| Accounts Receivable | ₩162.03 Billion | 18.5% |
| Inventory | ₩118.84 Billion | 13.6% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩15.82 Billion | 1.8% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Jeil Pharm's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Jeil Pharm (002620) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jeil Pharm's current assets represent 42.6% of total assets in 2025, a decrease from 67.1% in 2011.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2025, up from 5.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 18.5% of total assets.
Jeil Pharm Competitors by Total Assets
Key competitors of Jeil Pharm based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.44 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Bide Pharmatech Co. Ltd. A
SHG:688073
|
China | CN¥2.54 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥25.73 Billion |
Jeil Pharm - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.20 | 1.14 | 1.19 |
| Quick Ratio | 0.85 | 0.79 | 0.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩66.07 Billion | ₩44.07 Billion | ₩59.63 Billion |
Jeil Pharm - Advanced Valuation Insights
This section examines the relationship between Jeil Pharm's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.37 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.5% |
| Total Assets | ₩876.66 Billion |
| Market Capitalization | $71.68 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jeil Pharm's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jeil Pharm's assets decreased by 1.5% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jeil Pharm (2011–2025)
The table below shows the annual total assets of Jeil Pharm from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩876.66 Billion ≈ $594.10 Million |
-1.55% |
| 2024-12-31 | ₩890.43 Billion ≈ $603.43 Million |
+1.19% |
| 2023-12-31 | ₩880.00 Billion ≈ $596.36 Million |
+1.65% |
| 2022-12-31 | ₩865.68 Billion ≈ $586.66 Million |
-3.00% |
| 2021-12-31 | ₩892.42 Billion ≈ $604.78 Million |
+0.57% |
| 2020-12-31 | ₩887.40 Billion ≈ $601.37 Million |
+4.83% |
| 2019-12-31 | ₩846.47 Billion ≈ $573.64 Million |
-8.00% |
| 2018-12-31 | ₩920.09 Billion ≈ $623.53 Million |
+365.66% |
| 2017-12-31 | ₩197.59 Billion ≈ $133.90 Million |
-59.84% |
| 2016-12-31 | ₩491.98 Billion ≈ $333.41 Million |
+10.52% |
| 2015-12-31 | ₩445.17 Billion ≈ $301.68 Million |
+13.92% |
| 2012-12-31 | ₩390.77 Billion ≈ $264.82 Million |
+1.73% |
| 2011-12-31 | ₩384.13 Billion ≈ $260.32 Million |
-- |
About Jeil Pharm
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms i… Read more